NasdaqGM:IRON - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	104	-169	-146	N/A	7
12/31/2026	36	-185	-145	-270	10
12/31/2025	N/A	-160	-147	-117	9
3/31/2025	N/A	-116	-103	-102	N/A
12/31/2024	N/A	-109	-94	-94	N/A
9/30/2024	N/A	-103	-84	-84	N/A
6/30/2024	N/A	-91	-74	-74	N/A
3/31/2024	N/A	-81	-72	-72	N/A
12/31/2023	N/A	-76	-74	-73	N/A
9/30/2023	N/A	-64	-65	-65	N/A
6/30/2023	N/A	-66	-68	-68	N/A
3/31/2023	N/A	-60	-64	-64	N/A
12/31/2022	N/A	-47	-42	-42	N/A
9/30/2022	N/A	-44	-39	-39	N/A
6/30/2022	N/A	-37	-35	-34	N/A
3/31/2022	N/A	-37	-33	-33	N/A
12/31/2021	N/A	-36	-28	-28	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IRON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IRON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IRON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IRON's revenue (64% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: IRON's revenue (64% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IRON's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/16 01:36
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Disc Medicine, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Evan Seigerman	BMO Capital Markets Equity Research
Kristen Kluska	Cantor Fitzgerald & Co.
Douglas Tsao	H.C. Wainwright & Co.

Disc Medicine Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Disc Medicine, Inc., Annual General Meeting, Jun 11, 2025

Disc Medicine, Inc. Announces That the Presentation of Full Results from Phase 2 Aurora and Beacon Studies

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $225.499982 million.

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine: Potential Promise Amid Uncertainty

Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate

Disc Medicine Presents Positive Updated Results from Phase 1B Trial in Patients with Myelofibrosis and Anemia in an Oral Presentation At the 66Th American Society of Hematology Annual Meeting

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $29.7 million.

Disc Medicine, Inc. Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine: Achieving Functional Endpoint More Important

Disc Medicine, Inc. Announces Appointment of Steve Caffé as Chief Regulatory Officer

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $177.984 million.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria (EPP)

New major risk - Revenue and earnings growth

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Key Executive notifies of intention to sell stock

Disc Medicine: What's Behind The Huge Rally

Key Executive notifies of intention to sell stock

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Independent Director notifies of intention to sell stock

Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology (Ash) Annual Meeting

General Counsel notifies of intention to sell stock

General Counsel exercised options and sold US$176k worth of stock

General Counsel notifies of intention to sell stock

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Chief Financial Officer notifies of intention to sell stock

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association (EHA) 2023 Congress

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

No independent directors

Earnings and Revenue Growth Forecasts